DAVID DEUSER: Open Payments
NPI 1427237015 · BRUNSWICK, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,339 in 165 payments from 21 companies in 2025. Trend: 2023 $3,170 · 2024 $2,830 · 2025 $3,339
Food & beverage: $3,339
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 36 | $599 |
| Neuronetics, Inc. | 8 | $380 |
| Janssen Pharmaceuticals, Inc | 17 | $290 |
| Neurocrine BioSciences, Inc. | 16 | $262 |
| E.R. Squibb & Sons, L.L.C. | 12 | $253 |
| Alkermes, Inc. | 10 | $184 |
| Vanda Pharmaceuticals Inc. | 9 | $174 |
| Supernus Pharmaceuticals, Inc. | 8 | $156 |
| Tris Pharma Inc | 8 | $151 |
| Axsome Therapeutics, Inc. | 5 | $115 |
Products named: VRAYLAR, NEUROSTAR TMS THERAPY SYSTEM, INGREZZA, COBENFY, SPRAVATO, ARISTADA, FANAPT, Qelbree.
Industry payments across GA — which companies pay providers there.
